Solana Co (NASDAQ: HSDT)

Solana Company is a listed digital asset treasury that also operates a neurotechnology business focused on neurological wellness. The company’s primary activity is acquiring and holding Solana tokens (SOL) to provide shareholders with direct exposure to the Solana blockchain while seeking to increase SOL per share through staking, yield generation and disciplined capital‑markets activity. In parallel it develops, markets and sells the Portable Neuromodulation Stimulator (PoNS) device, a non‑implantable medical product used to treat gait and balance deficits in patients with conditions such as multiple sclerosis, stroke and traumatic brain injury.

Solana Company generates revenue mainly from the economic value of its SOL treasury, which includes staking rewards, lending income and potential gains from buying or selling SOL at favorable prices. The company may also earn fees from structured products, options‑based strategies and other treasury‑related activities that aim to enhance the yield on its digital asset holdings. Additionally the neurotechnology segment derives revenue from sales of the PoNS device and associated therapy services to healthcare providers and patients.

The company operates through the following segments:

• Digital Asset Treasury: This segment manages the acquisition, staking and active deployment of Solana tokens to generate yield and increase net asset value per share. Activities include direct SOL purchases, staking with third‑party validators, liquid staking, institutional lending, covered call programs and other traditional finance and decentralized finance strategies designed to optimize the economic use of the treasury while maintaining risk controls.

• Neurotechnology: This segment develops, manufactures and markets the PoNS device, a non‑implantable neuromodulation system that delivers mild electrical stimulation to the tongue to support gait and balance training. The segment also provides clinical training, patient support and therapy programs that accompany device use, and pursues regulatory clearances and commercial partnerships in the United States, Canada and Australia.

Solana Company occupies a niche position as a publicly traded digital asset treasury with a concentrated focus on Solana, distinguishing it from broader crypto‑exposure firms that hold multiple tokens. Its competitive advantages stem from a dedicated staking and yield‑generation framework, active treasury management and a formal relationship with the Solana ecosystem that may provide preferential access to network developments. In the neurotechnology space the company differentiates itself through the PoNS device’s FDA‑cleared indications for multiple indications and its combination of hardware with structured therapy, setting it apart from other neuromodulation products that lack comparable regulatory clearance or integrated treatment protocols.

The Digital Asset Treasury segment serves public market investors seeking regulated exposure to Solana, including institutional and retail shareholders who acquire the company’s equity to gain indirect access to SOL staking and price appreciation. The Neurotechnology segment sells the PoNS device to hospitals, rehabilitation clinics and physiotherapy centers, and ultimately treats patients suffering from neurological gait and balance disorders who obtain the device via prescription from qualified healthcare professionals.